Brief: Bioarctic Receives Positive Opinion For Orphan Medicinal Product Designation In EU
22/05/2025 14:26
May 22 (Reuters) - BioArctic AB BIOAb.ST: BIOARCTIC RECEIVES POSITIVE OPINION FOR ORPHAN MEDICINAL PRODUCT DESIGNATION IN THE EU FOR EXIDAVNEMAB IN MULTIPLE SYSTEM ATROPHY Source text: ID:nWkr7g9xFr Further company coverage: [BIOAb.ST] (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on BioArctic AB (publ)
See all newsBrief: BioArctic Gets Leqembi Pen Subcutaneous Formulation Approval In Japan
Brief: BioArctic Says Leqembi Subcutaneous Formulation Approved For Initiation Treatment In China
Brief: BioArctic Says Canada's Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement Of Leqembi
Sweden's BioArctic Q2 revenue falls despite higher Leqembi royalties
Brief: BioArctic Q2 Net Sales Down At SEK 247.5 Mln